Name:	opht_IncomeTaxesLineItems
Namespace Prefix:	opht_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Represents the amount of patient enrollment-based milestone revenue achieved by the entity.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementAmountOfEnrollmentBasedMilestoneAchieved
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of upfront fees received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementUpfrontFeesReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name:	us-gaap_IncomeTaxesPaidNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name:	us-gaap_OperatingLossCarryforwards
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash inflow from other borrowing not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromOtherDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=opht_NovartisPharmaAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opht_NovoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Income Taxes (Details 2) (USD $)	12 Months Ended		1 Months Ended		0 Months Ended
Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	May 31, 2014	May 19, 2014
Income taxes
Proceeds from the Novo Agreement	$ 83,333,000us-gaap_ProceedsFromOtherDebt	$ 41,667,000us-gaap_ProceedsFromOtherDebt
Income tax payments	40,200,000us-gaap_IncomeTaxesPaidNet
Forecast \| Minimum
Income taxes
Net operating losses	91,300,000
Novo A/S
Income taxes
Proceeds from the Novo Agreement	83,300,000
Novartis Pharma AG
Income taxes
Amount received	200,000,000			200,000,000
Patient enrollment-based milestone revenue achieved			50,000,000
Novartis Pharma AG \| Licensing and Commercialization Agreement
Income taxes
Amount received					200,000,000
Novartis Pharma AG \| Achievement of specified patient enrollment milestones \| Licensing and Commercialization Agreement
Income taxes
Patient enrollment-based milestone revenue achieved			$ 50,000,000